South Africa has introduced a new HIV prevention drug called Lenacapavir, which is injected every six months and is highly effective in preventing the virus. This rollout is significant as South Africa has the highest number of HIV cases globally, with about 8 million people living with the virus. The drug is being launched in 360 health facilities across high-burden areas. While South Africa has made progress in treating HIV, prevention remains a challenge, especially among young women aged 15 to 24. Lenacapavir offers a promising alternative to daily pills, which many find difficult to adhere to. However, limited funding means not everyone who needs the drug will have access to it. Experts believe that while Lenacapavir is a breakthrough, its success depends on effective implementation and increased funding.
QUESTION: How might the introduction of Lenacapavir change the future of HIV prevention and treatment in South Africa and beyond?
South Africa rolls out game-changing HIV shot amid funding shortfalls
